1nhaler has raised approximately $3 million in follow-on financing to advance development of its single-use cardboard dry powder inhaler (DPI), with the company targeting its first regulatory approval in 2027.

The funding round was led by Archangels, with additional backing from Scottish Enterprise and BBB Investments. The proceeds will support late-stage development of the company’s lead candidate, 1nhaler Salbutamol, which pairs its proprietary inhaler device with salbutamol, a widely used treatment for asthma.

A key priority is transferring the product’s manufacturing process to a contract manufacturing partner so clinical trial material can be produced. The company also plans to conduct a small clinical study to generate data for a regulatory submission, which it is targeting for late 2027.

The financing will also fund a manufacturing engineering study with equipment and production specialist Harro Höfliger. The work is intended to assess the requirements for scaling up commercial production of the inhaler. In parallel, 1nhaler plans to continue discussions with potential partners interested in applying its platform to other medicines.

1nhaler’s device is designed to address limitations in existing inhaler formats, including accessibility, cost and environmental considerations. Unlike conventional inhalers, which are typically made from plastic, the company’s single-dose DPI is constructed primarily from cardboard and has a compact footprint comparable to a credit card. It unfolds into a three-dimensional inhaler when needed.

The device incorporates a patented membrane-based delivery system and a limited number of components. According to the company, this design is intended to simplify manufacturing and support more cost-effective production at commercial scale. Following respiratory applications, the platform could also be adapted to deliver other dry powder medicines, including potential treatments for pain and vaccines.

The company is developing its technology against a backdrop of growing interest in pulmonary drug delivery, which can provide a needle-free route for administering medicines directly to the lungs. Inhaled therapies are used across a range of indications, including asthma, chronic obstructive pulmonary disease (COPD), influenza and certain neurological and psychiatric conditions.

Co-founder and CEO Lisa McMyn says the new investment will bring the company closer to advancing its lead product into clinical testing. She also pointed to the continued support of Archangels, Scottish Enterprise and BBB Investments as recognition of the technical and commercial progress made over the past year.

Archangels, which has backed 1nhaler since 2023, cited the device’s potential applications beyond its initial respiratory focus. Dr. Sarah Hardy, Director and Head of New Investments at Archangels, says interest from prospective partners across a broader range of drug applications has highlighted the platform’s versatility. She described clinical testing as an important step toward demonstrating the device’s performance in patients.

Derek Shaw, Director of Company Funding and Investment at Scottish Enterprise, says the investment reflects the organization’s commitment to helping Scottish companies develop and compete in international markets. He highlighted the health sector as an area of strength for Scotland’s economy.

For more information, visit https://www.1nhaler.com.